|Dr. Dale R. Pfost Ph.D.||CEO & Director||N/A||N/A||1957|
|Dr. Adi Mor George Ph.D.||Co-Founder, Chief Scientific Officer & Exec. Director||N/A||N/A||1982|
|Mr. Donald R. Marvin MBA||CFO, Exec. VP & COO||N/A||N/A||1953|
|Barbara Lindheim||Consulting VP of Investor & PR, Strategic Communications||N/A||N/A||N/A|
|Dr. Arnon Aharon M.D.||Chief Medical Officer||N/A||N/A||1969|
|Dr. David M. Weiner M.D.||Interim Chief Medical Officer||N/A||N/A||1965|
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.